Moral Moral P, Cabanero-Navalon M, Lopez-Leon P, Balastegui-Martin H, Martinez Mercader S, Mir A
Front Immunol. 2025; 15:1527514.
PMID: 39902048
PMC: 11788146.
DOI: 10.3389/fimmu.2024.1527514.
King P
Biomed Res Int. 2018; 2018:6802637.
PMID: 29744361
PMC: 5878907.
DOI: 10.1155/2018/6802637.
Karakoc Aydiner E, Kiykim A, Baris S, Ozen A, Barlan I
Turk Pediatri Ars. 2016; 51(1):8-14.
PMID: 27103859
PMC: 4829171.
DOI: 10.5152/TurkPediatriArs.2016.3058.
Dash C, Gascoigne E, Gillanders K, Gooi H
PLoS One. 2015; 10(7):e0131565.
PMID: 26222441
PMC: 4519338.
DOI: 10.1371/journal.pone.0131565.
Chapel H, Prevot J, Gaspar H, Espanol T, Bonilla F, Solis L
Front Immunol. 2015; 5:627.
PMID: 25566243
PMC: 4266088.
DOI: 10.3389/fimmu.2014.00627.
Expression of activation-induced cytidine deaminase gene in B lymphocytes of patients with common variable immunodeficiency.
Abolhassani H, Salek Farrokhi A, Pourhamdi S, Mohammadinejad P, Sadeghi B, Moazzeni S
Iran J Pediatr. 2014; 23(4):451-7.
PMID: 24427500
PMC: 3883376.
Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.
Lingman-Framme J, Fasth A
Drugs. 2013; 73(12):1307-19.
PMID: 23861187
DOI: 10.1007/s40265-013-0094-3.
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.
Wood P
Ther Clin Risk Manag. 2012; 8:157-67.
PMID: 22547934
PMC: 3333462.
DOI: 10.2147/TCRM.S22599.
Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.
Modell V, Gee B, Lewis D, Orange J, Roifman C, Routes J
Immunol Res. 2011; 51(1):61-70.
PMID: 21935653
DOI: 10.1007/s12026-011-8241-y.
A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W, Erdos M, Rossi P, Bernatowska E, Espanol T, Marodi L
Clin Exp Immunol. 2010; 161(3):512-7.
PMID: 20550545
PMC: 2962969.
DOI: 10.1111/j.1365-2249.2010.04187.x.
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.
Jacob S, Rajabally Y
Curr Neuropharmacol. 2010; 7(4):337-42.
PMID: 20514213
PMC: 2811867.
DOI: 10.2174/157015909790031166.
Clinical characteristics and outcomes of primary immunodeficiencies in Thai children: an 18-year experience from a tertiary care center.
Benjasupattananan P, Simasathein T, Vichyanond P, Leungwedchakarn V, Visitsunthorn N, Pacharn P
J Clin Immunol. 2009; 29(3):357-64.
PMID: 19184381
PMC: 7102384.
DOI: 10.1007/s10875-008-9273-5.
From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies.
Modell F, Puente D, Modell V
Immunol Res. 2009; 44(1-3):132-49.
PMID: 19140027
DOI: 10.1007/s12026-008-8092-3.
Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency.
Tarzi M, Grigoriadou S, Carr S, Kuitert L, Longhurst H
Clin Exp Immunol. 2009; 155(2):147-55.
PMID: 19128358
PMC: 2675244.
DOI: 10.1111/j.1365-2249.2008.03851.x.
Impact of a physician education and patient awareness campaign on the diagnosis and management of primary immunodeficiencies.
Pickett D, Modell V, Leighton I, Modell F
Immunol Res. 2007; 40(1):93-4.
PMID: 18058072
DOI: 10.1007/s12026-007-8013-x.
Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.
Wood P, Stanworth S, Burton J, Jones A, Peckham D, Green T
Clin Exp Immunol. 2007; 149(3):410-23.
PMID: 17565605
PMC: 2219316.
DOI: 10.1111/j.1365-2249.2007.03432.x.
Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
Berger M, Cunningham-Rundles C, Bonilla F, Melamed I, Bichler J, Zenker O
J Clin Immunol. 2007; 27(5):503-9.
PMID: 17479360
DOI: 10.1007/s10875-007-9096-9.
Early indicators of immunodeficiency in adults and children: protocols for screening for primary immunological defects.
Sewell W, Khan S, Dore P
Clin Exp Immunol. 2006; 145(2):201-3.
PMID: 16879237
PMC: 1809684.
DOI: 10.1111/j.1365-2249.2006.03126.x.
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho B
J Clin Immunol. 2006; 26(2):177-85.
PMID: 16758340
DOI: 10.1007/s10875-006-9002-x.
Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.
Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A
Qual Life Res. 2005; 14(7):1683-91.
PMID: 16119180
DOI: 10.1007/s11136-005-1746-x.